Quarterly report pursuant to Section 13 or 15(d)

Intangible Asset (Details Narrative)

v3.10.0.1
Intangible Asset (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Mar. 19, 2018
Oct. 04, 2017
Sep. 30, 2018
Sep. 30, 2018
Sep. 30, 2017
Purchase of software license       $ (20,500)
Capitalized cost     $ 3,037,147 3,037,147  
Business combination of tax basis     1,782 $ 1,782  
Number of shares acquired in exchange for common stock   31,745,242   2,090,301  
Precentage of issued and outstanding common stock diluted basis   90.00%      
Proceeds from common stock       $ 2,965,095
Amortization expense     200,256 $ 422,814
Weighted average amortization period for intangible asset       14 years  
Future amortization expense, year two     795,000 $ 795,000  
Future amortization expense,thereafter     788,000 788,000  
Subscription Receivable [Member]          
Proceeds from royalty receivable       8,000,000  
CoNCERT Pharmaceuticals, Inc [Member]          
Capitalized cost     11,038,929 11,038,929  
Transaction costs     $ 1,782 $ 1,782  
Option exercised in exchange for common stock $ 8,000,000        
Number of shares acquired in exchange for common stock 2,090,301        
Percentage of royalty 15.00%        
Proceeds from royalty receivable $ 8,000,000        
Proceeds from common stock $ 8,000,000